Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DYADIC INTERNATIONAL, INC.

(DYAI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

DYADIC INTERNATIONAL INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)

06/03/2021 | 04:35pm EDT

Item 1.01. Entry into a Material Definitive Agreement.

On May 28, 2021, Dyadic International (USA), Inc., a subsidiary of Dyadic International, Inc., (hereinafter collectively referred to as "Dyadic" or the "Company") entered into an amendment to its Master Services Agreement (the "Amended MSA") with CR2O B.V. ("CR2O"), which was previously signed on March 18, 2021. The Amended MSA restated the Company's engagement with CR2O to oversee and perform certain pre-clinical and clinical trial services related to the Company's C1 produced SARS-CoV-2 receptor binding domain (RBD) of the SARS-CoV-2 spike protein COVID-19 vaccine candidate ("DYAI-100") which the Company is moving towards an anticipated Phase 1 clinical trial. The Amended MSA also included Work Order Number 02 between the Company and CR2O, also dated May 28, 2021, where CR2O will continue oversee and perform additional pre-clinical trial services relating to the Company's COVID-19 DYAI-100. The Amended MSA is effective retroactively on March 18, 2021 (the Effective Date") and the term of the MSA remains for a period of five (5) years from the Effective Date.

The foregoing description of the MSA and the Work Order is qualified in its entirety by reference to the complete terms and conditions of the MSA and the Work Order, which are filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.



Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is being furnished herein:
      Exhibit
      Number          Description

       10.1             Master Services Agreement and Work Order, between Dyadic
                      International (USA), Inc. and CR2O B.V., Dated May 28, 2021.
                      Specific items in this exhibit have been redacted, as market
                      by three asterisks[***].
        104           Cover page Interactive Data File (embedded within the Inline
                      XBRL document)

© Edgar Online, source Glimpses

All news about DYADIC INTERNATIONAL, INC.
07/29DYADIC INTERNATIONAL : Dyadic International, Inc.
AQ
07/29DYADIC INTERNATIONAL : to Report Second Quarter 2021 Financial Results
PU
07/27DYADIC INTERNATIONAL : Signs Technology Transfer, Licensing Deal With South Afri..
MT
07/27DYADIC INTERNATIONAL : ANNOUNCES TECHNOLOGY TRANSFER AND LICENSING AGREEMENT WIT..
PU
07/27DYADIC INTERNATIONAL INC : Entry into a Material Definitive Agreement, Financial..
AQ
07/27DYADIC INTERNATIONAL INC : Other Events, Financial Statements and Exhibits (form..
AQ
07/27DYADIC INTERNATIONAL : Announces Technology Transfer and Licensing Agreement Wit..
AQ
07/27Dyadic Announces Technology Transfer and Licensing Agreement With South Afric..
CI
06/28Dyadic's C1 Production Platform Utilized in ZAPI Study Published in “VA..
GL
06/28Dyadic International, Inc.’s C1 Production Platform Utilized in ZAPI Study Pu..
CI
More news
Financials (USD)
Sales 2021 2,80 M - -
Net income 2021 -11,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,60x
Yield 2021 -
Capitalization 99,5 M 99,5 M -
Capi. / Sales 2021 35,5x
Capi. / Sales 2022 30,1x
Nbr of Employees 6
Free-Float 48,6%
Chart DYADIC INTERNATIONAL, INC.
Duration : Period :
Dyadic International, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DYADIC INTERNATIONAL, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Last Close Price 3,61 $
Average target price 10,00 $
Spread / Average Target 177%
EPS Revisions
Managers and Directors
Mark A. Emalfarb President, Chief Executive Officer & Director
Ping W. Rawson Chief Financial Officer
Michael P. Tarnok Chairman
Ronen Tchelet Vice President-Research & Business Development
Seth J. Herbst Independent Director
Sector and Competitors
1st jan.Capi. (M$)
DYADIC INTERNATIONAL, INC.-32.90%99
MODERNA, INC.230.85%138 784
LONZA GROUP AG21.77%56 806
IQVIA HOLDINGS INC.38.81%47 656
CELLTRION, INC.-27.16%31 282
SEAGEN INC.-16.10%26 668